Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QURE Stock Forecast 2026-2027
$39.36
Current Price
$2.77B
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to QURE Price Targets
+136.5%
To High Target of $93.09
+65.0%
To Median Target of $64.96
-8.3%
To Low Target of $36.11
QURE Price Momentum
-7.7%
1 Week Change
-15.0%
1 Month Change
+162.6%
1 Year Change
+64.5%
Year-to-Date Change
-45.0%
From 52W High of $71.50
+350.9%
From 52W Low of $8.73
📊 TOP ANALYST CALLS
Did QURE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if uniQure is one of their latest high-conviction picks.
Latest QURE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, QURE has a bullish consensus with a median price target of $64.96 (ranging from $36.11 to $93.09). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $39.36, the median forecast implies a 65.0% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QURE Analyst Ratings
11
Buy
2
Hold
0
Sell
QURE Price Target Range
Low
$36.11
Average
$64.96
High
$93.09
Current: $39.36
Latest QURE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QURE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 29, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $80.00 |
| Jun 25, 2026 | Mizuho | Uy Ear | Outperform | Maintains | $68.00 |
| Jun 18, 2026 | Barclays | Overweight | Upgrade | $N/A | |
| Jun 18, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Jun 18, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Jun 18, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 6, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 30, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Apr 20, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Mar 23, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Mar 11, 2026 | Mizuho | Outperform | Upgrade | $N/A | |
| Mar 10, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 9, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 9, 2026 | RBC Capital | Outperform | Upgrade | $N/A | |
| Mar 9, 2026 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Mar 3, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Mar 3, 2026 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Mar 3, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Mizuho | Neutral | Downgrade | $N/A | |
| Mar 2, 2026 | Leerink Partners | Outperform | Maintains | $N/A |
uniQure N.V. (QURE) Competitors
The following stocks are similar to uniQure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
uniQure N.V. (QURE) Financial Data
uniQure N.V. has a market capitalization of $2.77B with a P/E ratio of -11.6x. The company generates $18.09M in trailing twelve-month revenue with a 89.5% profit margin.
Revenue growth is +127.3% quarter-over-quarter, while maintaining an operating margin of -1,321.1% and return on equity of -228.2%.
Valuation Metrics
Market Cap
$2.77B
Enterprise Value
$2.58B
P/E Ratio
-11.6x
PEG Ratio
-3.2x
Price/Sales
155.8x
Growth & Margins
Revenue Growth (YoY)
+127.3%
Gross Margin
+93.9%
Operating Margin
-1,321.1%
Net Margin
+89.5%
EPS Growth
+127.3%
Financial Health
Cash/Price Ratio
+23.6%
Current Ratio
10.4x
Debt/Equity
365.4x
ROE
-228.2%
ROA
-17.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
uniQure N.V. (QURE) Business Model
About uniQure N.V.
What They Do
Biotechnology company specializing in gene therapy.
Business Model
uniQure N.V. develops single-treatment gene therapies targeting rare and severe diseases, generating revenue through commercial activities and partnerships focused on AAV-based therapies. Their platform enables the delivery of genetic material to restore protein function, particularly in liver and central nervous system disorders.
Additional Information
Founded in 1998 and headquartered in Amsterdam, uniQure has a robust pipeline addressing unmet medical needs, including treatments for Huntington’s disease, ALS, and hemophilia. Their internal manufacturing capabilities enhance their research and development processes, positioning them as a leader in advanced gene therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
221
CEO
Mr. Matthew Craig Kapusta CPA
Country
Netherlands
IPO Year
2014
Website
www.uniqure.comuniQure N.V. (QURE) Latest News & Analysis
Latest News
16 Stocks That Could Squeeze Shorts This Month
15 days ago
Quick Summary
Investors face challenges as profit-taking in memory stocks and a shift in semiconductor investments complicate market forecasts.
Why It Matters
Profit-taking in memory stocks amid semiconductor rotation signals volatility, complicating investment decisions and potentially impacting market trends and stock valuations.
Source: Schaeffers Research
Market Sentiment:
Neutral
Quick Summary
uniQure N.V. (QURE) has reached a significant support level, suggesting a potential buying opportunity for investors based on technical analysis.
Why It Matters
uniQure's significant support level suggests potential price stability, indicating a favorable entry point for investors looking for technical trading opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
uniQure N.V. announced a public offering of 4,945,055 shares at $45.50 each, aiming for gross proceeds of approximately $225 million. Closing expected around June 25, 2026.
Why It Matters
uniQure's $225 million capital raise indicates strong investor interest and funding for future developments, potentially impacting share value and market position in gene therapy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
uniQure N.V. closed a public offering of 5,686,813 shares at $45.50 each, raising approximately $259 million before expenses. All shares were sold by the company.
Why It Matters
uniQure's $259 million capital raise enhances its financial position, potentially funding further research and development, which may drive future growth and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
uniQure N.V. has launched a $150 million public offering of ordinary shares and pre-funded warrants, with an option for underwriters to purchase an additional $22.5 million. Completion is subject to market conditions.
Why It Matters
uniQure's $150 million public offering signals potential dilution of existing shares but also raises capital for growth. Investors should assess its impact on stock value and future projects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
uniQure reports early data from the AMT-260 epilepsy study, showing 79-100% seizure reductions in three patients with no serious safety concerns.
Why It Matters
Positive early data from uniQure's AMT-260 study suggests potential for effective epilepsy treatment, boosting investor confidence and likely increasing stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About QURE Stock
What is uniQure N.V.'s (QURE) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, uniQure N.V. (QURE) has a median price target of $64.96. The highest price target is $93.09 and the lowest is $36.11.
Is QURE stock a good investment in 2027?
According to current analyst ratings, QURE has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $39.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QURE stock?
Wall Street analysts predict QURE stock could reach $64.96 in the next 12 months. This represents a 65.0% increase from the current price of $39.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is uniQure N.V.'s business model?
uniQure N.V. develops single-treatment gene therapies targeting rare and severe diseases, generating revenue through commercial activities and partnerships focused on AAV-based therapies. Their platform enables the delivery of genetic material to restore protein function, particularly in liver and central nervous system disorders.
What is the highest forecasted price for QURE uniQure N.V.?
The highest price target for QURE is $93.09 from at , which represents a 136.5% increase from the current price of $39.36.
What is the lowest forecasted price for QURE uniQure N.V.?
The lowest price target for QURE is $36.11 from at , which represents a -8.3% decrease from the current price of $39.36.
What is the overall QURE consensus from analysts for uniQure N.V.?
The overall analyst consensus for QURE is bullish. Out of 4 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $64.96.
How accurate are QURE stock price projections?
Stock price projections, including those for uniQure N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 9:12 PM UTC